Person:
Brizzi, Kate

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Brizzi

First Name

Kate

Name

Brizzi, Kate

Filters

20171

Settings

Author's Publications: search.filters.isAuthorOfPublication.7f340ed1-9b28-4640-a2d5-cc60cf150f3a

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Validation of a smartphone-based EEG among people with epilepsy: A prospective study
    (Springer Nature, 2017) McKenzie, Erica D.; Lim, Andrew S. P.; Leung, Edward C. W.; Cole, Andrew; Lam, Alice; Eloyan, Ani; Nirola, Damber K.; Tshering, Lhab; Thibert, Ronald; Garcia, Rodrigo; Bui, Esther; Deki, Sonam; Lee, Liesly; Clark, Sarah J.; Cohen, Joseph M.; Mantia, Jo; Brizzi, Kate; Sorets, Tali R.; Wahlster, Sarah; Borzello, Mia; Stopczynski, Arkadiusz; Cash, Sydney; Mateen, Farrah
    Our objective was to assess the ability of a smartphone-based electroencephalography (EEG) application, the Smartphone Brain Scanner-2 (SBS2), to detect epileptiform abnormalities compared to standard clinical EEG. The SBS2 system consists of an Android tablet wirelessly connected to a 14-electrode EasyCap headset (cost ~300USD). SBS2 and standard EEG were performed in people with suspected epilepsy in Bhutan (2014-2015), and recordings were interpreted by neurologists. Among 205 participants (54% female, median age 24 years), epileptiform discharges were detected on 14% of SBS2 and 25% of standard EEGs. The SBS2 had 39.2% sensitivity (95% confidence interval (CI) 25.8%, 53.9%) and 94.8% specificity (95% CI 90.0%, 97.7%) for epileptiform discharges with positive and negative predictive values of 0.71 (95% CI 0.51, 0.87) and 0.82 (95% CI 0.76, 0.89) respectively. 31% of focal and 82% of generalized abnormalities were identified on SBS2 recordings. Cohen’s kappa (κ) for the SBS2 EEG and standard EEG for the epileptiform versus non-epileptiform outcome was κ=0.40 (95% CI 0.25, 0.55). No safety or tolerability concerns were reported. Despite limitations in sensitivity, the SBS2 may become a viable supportive test for the capture of epileptiform abnormalities, and extend EEG access to new, especially resource-limited, populations at a reduced cost.